Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma

BACKGROUND: Lenvatinib + pembrolizumab is approved for the first-line treatment of advanced renal cell carcinoma (RCC). In the CLEAR trial, the combination showed statistically significant/clinically meaningful improvements in overall survival (OS), progression-free survival (PFS), and objective res...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chung-Han, Yogesh Shah, Amishi, Rao, Arpit, Taylor, Matthew H, Pinto, Alvaro, Girones Sarrio, Regina, Lee Cohn, Allen, Asim Bilen, Mehmet, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Heinrich, Daniel, Perini, Rodolfo, Kubiak, Peter, Huang, Jie, Motzer, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Oral Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445556/
http://dx.doi.org/10.1093/oncolo/oyad216.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445556/
http://dx.doi.org/10.1093/oncolo/oyad216.006

Ejemplares similares